Results 201 to 210 of about 69,773 (297)

Fruquintinib Plus TAS‐102 With or Without SBRT as Third‐ Or Later‐Line Therapy for Metastatic Colorectal Cancer: Preliminary Results From a Prospective Phase II Trial

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Both fruquintinib and TAS‐102 monotherapies are guideline‐recommended for third‐line treatment of metastatic colorectal cancer (mCRC). This study aimed to analyze the preliminary outcomes of fruquintinib combined with TAS‐102, with or without stereotactic body radiation therapy (SBRT), as a third‐ or later‐line therapy for mCRC.
Yi Wang, Jianfen Xu, Linchun Liang, Yunjie Chen, Leizheng Fei, Jing Hu, Jianjiong Li, Yi Lu, Feng Ren, Ke Chen, Yanping Shen, Qingsong Tao, Zhi Fang, Kaitai Liu, Hua Ye, Jing Zhang, Yunbao Xu, Haoxun Mao, Chen Zhang, Chuangzhou Rao   +19 more
wiley   +1 more source

Surgical Management of Stage IV Melanoma: Clinical, Molecular, and Therapeutic Considerations. [PDF]

Int J Mol Sci
Uche IK, Lyons JM.
europepmc   +1 more source

Clinical Characteristics, Gene Mutation Profiles and Prognosis of Patients With Acute Myeloid Leukemia Carrying PHF6 Mutations

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Background Plant Homeodomain Finger Protein 6 (PHF6) gene mutations are rare in acute myeloid leukemia (AML), with unclear mechanisms and uncertain prognostic value. They may compromise risk stratification and treatment decisions. This study analyzed clinical features and survival outcomes in PHF6‐mutated AML patients, evaluating the impact of
Dongmei Wang, Hanzhang Pan, Yungui Wang, Huan Xu, Lin Liu, Yuting Xu, Hongyan Tong   +6 more
wiley   +1 more source

Melanoma: Pathogenesis and Targeted Therapy. [PDF]

MedComm (2020)
Fu Y, Liu J, Mo Z, Wang B, Deng Y, Jiang Y.   +5 more
europepmc   +1 more source

NRAS NP_002515.1:p.G12V [PDF]

, 2020
openaire   +1 more source

Pulmonary Cryptococcal Infection Complicating Gefitinib Therapy in a Patient With EGFR L858R‐Positive Lung Adenocarcinoma: A Case Report

Clinical Case Reports, Volume 14, Issue 5, May 2026.
ABSTRACT In patients with EGFR‐mutant lung adenocarcinoma receiving gefitinib or other EGFR‐TKIs, the development of new pulmonary nodules should not be hastily attributed to disease progression; secondary pulmonary cryptococcosis should be considered in the differential diagnosis.
Yun Wang, Qianyu Wang, Jiangrong Liao, Yuxiang Zhou, Fang Yang, Gui feng Li, Chunyan Wu, Ting Jiang   +7 more
wiley   +1 more source

AXL is a novel ERK5/KLF4 target in MEK inhibitor-treated melanoma. [PDF]

Neoplasia
Paudel R, Goller S, Schwarz S, Meder K, Goebeler M, Schmidt M.   +5 more
europepmc   +1 more source

NRAS Protein Variant [PDF]

, 2020
openaire   +1 more source

Analysis of PLEKHS1 promoter mutation in preoperative thyroid nodule samples

Cancer Cytopathology, Volume 134, Issue 5, May 2026.
Abstract Indeterminate thyroid nodules carry a wide range of malignancy prevalence, necessitating incorporation of molecular testing to guide management. Molecular test results help guide prognosis to a certain extent, but additional prognostic factors need to be identified.
Sarah Azad, Timothy E. Graham, Shiri Levy, Evana Velanzuela‐Sheker, David Bimston, Andrea Ferenczi, Yang Chen, Mohammed Alshalalfa, Yangyang Hao, Joshua P. Klopper, Richard T. Kloos, Anupam Kotwal   +11 more
wiley   +1 more source

Growing Sodiophilic ZnO Nanorod Arrays on Al Substrate for High-Energy-Density Anode-Free Na Batteries. [PDF]

J Am Chem Soc
An Y, Pei Z, Luan D, Lou XWD.
europepmc   +1 more source